Today, a Director at EyePoint Pharmaceuticals Inc (EYPT), Douglas Evan Godshall, bought shares of EYPT for $29.75K.
Following this transaction Douglas Evan Godshall’s holding in the company was increased by 136% to a total of $52.81K. This is Godshall’s first transaction since reporting a Sell transaction on VTL back in September 2018
See today’s analyst top recommended stocks >>
Based on EyePoint Pharmaceuticals Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $2.44 million and GAAP net loss of $11.59 million. In comparison, last year the company earned revenue of $928K and had a GAAP net loss of $6.98 million. Currently, EyePoint Pharmaceuticals Inc has an average volume of 11.2K.
Starting in April 2018, EYPT received 24 Buy ratings in a row.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
